226 related articles for article (PubMed ID: 17582067)
1. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
2. Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.
Thakur CP; Kumar A; Mitra DK; Roy A; Sinha AK; Ranjan A
Am J Trop Med Hyg; 2010 Nov; 83(5):1040-3. PubMed ID: 21036834
[TBL] [Abstract][Full Text] [Related]
3. Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Edwards T; Omollo R; Khalil EA; Yifru S; Musa B; Musa A; Wasunna M; Smith PG; Royce C; Ellis S; Balasegaram M; Hailu A
Trials; 2011 Mar; 12():66. PubMed ID: 21375777
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases.
de Silva AA; Pacheco e Silva Filho Á; Sesso Rde C; Esmeraldo Rde M; de Oliveira CM; Fernandes PF; de Oliveira RA; de Silva LS; de Carvalho VP; Costa CH; Andrade JX; da Silva DM; Chaves RV
BMC Infect Dis; 2015 Feb; 15():96. PubMed ID: 25877483
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of treatment efficacy in human visceral leishmaniasis.
Roy S; Moulik S; Chaudhuri SJ; Ghosh MK; Goswami RP; Saha B; Chatterjee M
Trans R Soc Trop Med Hyg; 2024 May; 118(5):343-345. PubMed ID: 38223920
[TBL] [Abstract][Full Text] [Related]
6. Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India.
Sinha PK; Jha TK; Thakur CP; Nath D; Mukherjee S; Aditya AK; Sundar S
J Trop Med; 2011; 2011():645203. PubMed ID: 22174722
[TBL] [Abstract][Full Text] [Related]
7. Micronutrient levels and their effects on the prognosis of visceral leishmaniasis treatment, a prospective cohort study.
Feleke BE; Feleke TE
BMC Infect Dis; 2020 Nov; 20(1):867. PubMed ID: 33213392
[TBL] [Abstract][Full Text] [Related]
8. Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review.
Chhajed R; Dahal P; Singh-Phulgenda S; Brack M; Naylor C; Sundar S; Alves F; Stepniewska K; Guerin PJ
Lancet Reg Health Southeast Asia; 2024 Mar; 22():100317. PubMed ID: 38482151
[TBL] [Abstract][Full Text] [Related]
9. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Sundar S; Singh A; Rai M; Prajapati VK; Singh AK; Ostyn B; Boelaert M; Dujardin JC; Chakravarty J
Clin Infect Dis; 2012 Aug; 55(4):543-50. PubMed ID: 22573856
[TBL] [Abstract][Full Text] [Related]
11. Leishmaniasis worldwide and global estimates of its incidence.
Alvar J; Vélez ID; Bern C; Herrero M; Desjeux P; Cano J; Jannin J; den Boer M;
PLoS One; 2012; 7(5):e35671. PubMed ID: 22693548
[TBL] [Abstract][Full Text] [Related]
12. Paromomycin in the treatment of leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
[TBL] [Abstract][Full Text] [Related]
13. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
14. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
15. Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M; Farhoudi R
Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
[TBL] [Abstract][Full Text] [Related]
16. Leishmaniasis: a review.
Torres-Guerrero E; Quintanilla-Cedillo MR; Ruiz-Esmenjaud J; Arenas R
F1000Res; 2017; 6():750. PubMed ID: 28649370
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous leishmaniasis.
Reithinger R; Dujardin JC; Louzir H; Pirmez C; Alexander B; Brooker S
Lancet Infect Dis; 2007 Sep; 7(9):581-96. PubMed ID: 17714672
[TBL] [Abstract][Full Text] [Related]
18. Leishmaniasis.
Burza S; Croft SL; Boelaert M
Lancet; 2018 Sep; 392(10151):951-970. PubMed ID: 30126638
[TBL] [Abstract][Full Text] [Related]
19. Paromomycin.
Davidson RN; den Boer M; Ritmeijer K
Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):653-60. PubMed ID: 18947845
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.
Lalhmangaihzuala S; Vanlaldinpuia K; Khiangte V; Laldinpuii Z; Liana T; Lalhriatpuia C; Pachuau Z
Mol Divers; 2024 Mar; ():. PubMed ID: 38554170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
